Exploring the vital role of animal models in oncology and how new technologies are complementing traditional approaches
For nearly a century, the fight against cancer has been waged with an unlikely array of allies—creatures that swim, scurry, and live their lives in laboratory facilities around the world. From specially bred mice to translucent zebrafish, animal models have been the unsung heroes of oncology, allowing scientists to unravel the complex mysteries of cancer biology and test potential treatments before they ever reach human patients.
This partnership has been instrumental in every major cancer breakthrough, from the development of chemotherapy to revolutionary immunotherapies.
Today, this longstanding research paradigm is at a crossroads. With recent initiatives from the National Institutes of Health (NIH) to reduce animal testing and the rise of sophisticated alternatives, the role of our animal allies is rapidly evolving 1 .
The fundamental question remains: why do we use animals in cancer research? The answer lies in biological similarity. Despite our obvious differences, mice share approximately 97.5% of their working DNA with humans, making them remarkably accurate models for human disease processes 1 .
The laboratory mouse reigns supreme in cancer research, and for good reason. Their genetic malleability allows scientists to create remarkably precise models of human cancers.
While mouse models have traditionally dominated cancer research, zebrafish have made a splash in recent decades thanks to their unique advantages.
Allow researchers to directly observe cancer processes in real-time under a microscope 1 .
Ideal for large-scale genetic and drug screening studies.
"The zebrafish stands out as a tremendous system to model human blood disease" - Dr. Leonard Zon of Harvard University Stem Cell Institute 1
| Model Type | Key Features | Primary Research Applications |
|---|---|---|
| Mouse Models | Genetic similarity to humans; modifiable immune system | Drug testing, cancer progression studies, immunotherapy research |
| Zebrafish Models | Transparent embryos; large brood sizes; rapid development | Genetic screening, visualization of metastasis, drug discovery |
| Patient-Derived Xenografts | Preserves human tumor characteristics | Personalized medicine, drug response prediction, biomarker identification |
The true power of animal models is best illustrated through specific breakthroughs they've enabled. One remarkable example comes from the Zon Laboratory, where research on zebrafish blood stem cells ultimately led to an improved treatment for human patients.
The team added various chemicals to the water of zebrafish tanks, leveraging the species' permeable skin to efficiently test compounds.
They discovered that a chemical called dimethyl prostaglandin E2 (PGE2) significantly increased blood stem cell production in the living fish.
The finding was then translated to mice—researchers treated mouse bone marrow with the chemical, then performed "competitive transplants" with untreated marrow.
Finally, the approach was tested in 12 patients without sibling matches receiving cord blood transplants. One cord blood sample was treated with dimethyl PGE2, while another from the same donor remained untreated as a control 1 .
This research cascade—from zebrafish discovery to human application—demonstrated the profound potential of thoughtfully designed animal studies. The treated cord blood led to better engraftment in patients, and since the initial trial, approximately 150 patients have been treated with dimethyl PGE2 before transplant 1 .
This breakthrough highlights how animal models, used strategically, can directly lead to life-saving human therapies.
| Research Stage | Finding | Significance |
|---|---|---|
| Zebrafish Screening | Dimethyl PGE2 increases blood stem cells | Initial discovery enabled by zebrafish transparency and permeability |
| Mouse Validation | Treated stem cells showed better engraftment | Confirmed effect in mammalian system closer to humans |
| Human Trial | Improved engraftment in patients | Direct translation to clinical benefit for transplant recipients |
What does it take to conduct cancer research using animal models? Here's a look at the key tools and reagents that make this work possible:
Gene editing technology used for creating specific cancer mutations in animal models.
Human tumor samples implanted in mice for studying personalized treatment responses.
Cancer-causing chemicals like DMH and AOM for inducing colorectal cancer in models for study 7 .
Animals with disabled immune systems for accepting human tissue grafts without rejection.
Glowing markers for visualization used in tracking cancer cells and metastasis in transparent models.
Sophisticated microscopy and imaging systems for real-time observation of cancer processes.
While animal models continue to be indispensable, the field is rapidly evolving with new technologies that complement—and in some cases reduce—their use. The NIH recently announced a new initiative to reduce animal use in funded research by expanding human and AI-based innovations 1 .
One of the most exciting developments is the creation of organoids—three-dimensional, simplified versions of organs grown from stem cells that mimic key aspects of the real thing.
"They have the benefit of being human," explains Dr. Kellie Machlus of Harvard Medical School. "In our case, they're derived from human-induced pluripotent stem cells" 1 .
Cancer cells from patients can be added to these organoids, where they survive longer than in traditional culture systems, allowing for personalized treatment testing.
At the cutting edge of innovation are computational models that simulate biological systems, disease pathways, and drug interactions.
These AI-powered systems can analyze massive datasets to identify patterns and predict treatment outcomes. For instance, one computational model of CAR T-cell immunotherapy successfully predicted individualized treatment responses 1 .
These virtual models can rapidly test thousands of potential treatment combinations that would be logistically impossible in traditional laboratory settings.
Despite these advances, most researchers agree that these new technologies will complement rather than completely replace animal models for the foreseeable future.
"I think there's no substitute for an in vivo model... You can model things pretty well with AI, and it develops potential mechanisms and hypotheses to test, but using it as proof that something is actually going to work is pretty difficult" - Dr. Zon 1
"You're never going to understand toxicities that could impact other organs. In an animal, you have all the organ systems... I think the best way to use them is to combine the models and understand the limitations of each" - Dr. Machlus 1
The landscape of cancer research is transforming before our eyes. The long-standing reliance on animal models is giving way to a more nuanced, integrated approach that combines the proven value of animal studies with the promising potential of human-based models and computational power.
This evolution is driven not only by ethical considerations but by the scientific imperative to develop more accurate, efficient, and human-relevant research methods.
As we look to the future, the most promising path appears to be one of synthesis—where zebrafish help us visualize basic biological processes, mouse models test therapeutic concepts in complex living systems, organoids provide human-specific insights at the tissue level, and computational models analyze patterns across massive datasets. Each approach compensates for the limitations of the others, creating a research ecosystem far more powerful than any single method could be alone.
The heroes of cancer research are indeed still furry and scaly—but they're increasingly joined by digital algorithms and tiny organ-like structures in dishes. Together, this diverse toolkit continues to advance our understanding of cancer, bringing us closer to the day when this complex set of diseases can be effectively managed, treated, and ultimately prevented.